Literature DB >> 28192751

RETRACTED: Ameliorative potential of linagliptin and/or calcipotriol on bleomycin-induced lung fibrosis: In vivo and in vitro study.

Ahmed M Kabel1, Maaly A Abd Elmaaboud2, Aliaa Atef3, Mohammed H Baali4.   

Abstract

This article has been retracted: please see Elsevier Policy on Article Withdrawal (https://www.elsevier.com/about/our-business/policies/article-withdrawal). This article has been retracted due to the authors’ plagiarism of text and images from the work of Eman Said Abd-Elkhalek, Hatem Abdel-Rahman Salem, Ghada Mohamed SuddeK, Marwa Ahmed Zaghloul and Ramy Ahmed Abdel-Salam, Faculties of Pharmacy and Medicine, Mansoura University, Mansoura, Egypt.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bleomycin; Calcipotriol; Linagliptin; Pulmonary fibrosis; Study

Mesh:

Substances:

Year:  2017        PMID: 28192751     DOI: 10.1016/j.etap.2017.02.008

Source DB:  PubMed          Journal:  Environ Toxicol Pharmacol        ISSN: 1382-6689            Impact factor:   4.860


  2 in total

1.  Characterizing drug-related adverse events by joint analysis of biomedical and genomic data: A case study of drug-induced pulmonary fibrosis.

Authors:  Alex Jiang; Anil G Jegga
Journal:  AMIA Jt Summits Transl Sci Proc       Date:  2018-05-18

2.  1α,25-dihydroxyvitamin D3 Attenuates TGF-β-Induced Pro-Fibrotic Effects in Human Lung Epithelial Cells through Inhibition of Epithelial-Mesenchymal Transition.

Authors:  Fei Jiang; Yong Yang; Lian Xue; Bingyan Li; Zengli Zhang
Journal:  Nutrients       Date:  2017-09-06       Impact factor: 5.717

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.